FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

AtriCure, Inc. ATRC

Strong (graded 2026-07-21, not re-checked)   broader-coverage candidate · AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe,

On FrontierLab's discovery record since 2026-06-12 (10 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Strong" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-07-21), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)15%
Gross margin75.5%
Gross profits / assets0.65
Rule of 4014.6
Net margin-0.4%
Cash runway (months)
PEG
Price / sales3.2

Quality checklist

Fundamentals — snapshot as of 2026-07-21

StageEstablished
Share issuance (YoY)3.5% · modest issuance
Moat
TAM
P/E (trailing)
EPS (trailing)$-0.10
Burn multiple
Gross-margin trend (pts)0.9
Cash / assets0.23
Net debt / EBITDA-2.9
Statements as ofQ1 FY2026 · filed 2026-05-06

Momentum context — a snapshot from 2026-07-21, not current

Price at surface$34.77 (as of 2026-07-21)
52-week range$25.36 – $43.18
% off 52-wk high-19.5%
RSI (14)67
Relative volume

Risk flags

Burning cash — operating margin is negative.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-07-21 (end-of-day). How grades are computed →